RedHill Biopharma Ltd. (RDHL)
NCM · Healthcare · Drug Manufacturers - Specialty & Generic
Closing price as of 2026-07-30 · Source: TEK2day Finance
Key Metrics
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 61.8M | 0.00 | 0.00 | 286K |
| Gross Profit | 28.5M | 3.1M | 4.9M | |
| Operating Income | -42.8M | -9.5M | -6.5M | -7.9M |
| Net Income | -71.7M | 23.9M | -8.3M | -429K |
| Diluted EPS | $-1,200.00 | $100.00 | $0.00 | $nan |